---
trial_id: 257
discovery_date: 2022-03-29 21:28:27.990230
date: 2022-03-29 21:28:27.990230
title: "A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros..."
summary: |
  <p>EudraCT Number: 2019-004980-36<br />Sponsor Protocol Number: MS200527-0082<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2020-09-21<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/NO">NO</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SI">SI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/IT">IT</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004980-36'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2019-004980-36<br />Sponsor Protocol Number: MS200527-0082<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2020-09-21<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/NO">NO</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SI">SI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/IT">IT</a> (Ongoing)</p>